ADMA Biologics (NASDAQ:ADMA) Rating Reiterated by Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 0.10% from the stock’s previous close.

ADMA has been the subject of a number of other reports. HC Wainwright boosted their price target on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Mizuho increased their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.98 on Friday. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $20.16. The business has a 50 day moving average price of $15.77 and a two-hundred day moving average price of $10.96. The firm has a market cap of $4.63 billion, a PE ratio of -999.00 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business’s revenue was up 78.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.02) EPS. Sell-side analysts expect that ADMA Biologics will post 0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Jerrold B. Grossman sold 136,861 shares of ADMA Biologics stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the sale, the director now owns 467,305 shares of the company’s stock, valued at $8,070,357.35. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently bought and sold shares of ADMA. Viewpoint Capital Management LLC lifted its stake in shares of ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares during the period. Quest Partners LLC acquired a new stake in ADMA Biologics in the second quarter worth approximately $29,000. Arizona State Retirement System boosted its stake in ADMA Biologics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock valued at $689,000 after purchasing an additional 2,645 shares in the last quarter. Eagle Asset Management Inc. increased its position in shares of ADMA Biologics by 20.2% during the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 4,367 shares during the period. Finally, CWM LLC raised its stake in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.